SAN DIEGO, Jan. 5 /PRNewswire/ -- Idun Pharmaceuticals announced today that Steven J. Mento, Ph.D., President and CEO of Idun, will give a corporate presentation at the 23rd Annual JP Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel at 1:30p.m. on Monday, January 10, 2005. Dr. Mento will give an overview of Idun programs including discussion of Idun's lead clinical candidate, IDN-6556, which is in Phase 2 clinical studies for hepatitis and liver transplantation, as well as updates on the preclinical programs in asthma and cancer.
Idun Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the areas of liver disease, inflammation, and cancer. Idun's lead product candidate, IDN-6556, is in clinical studies for both liver transplantation and in patients infected with Hepatitis C virus. The company has a number of product candidates in advanced preclinical development for inflammation and cancer. Idun has an extensive patent portfolio comprised of 150 issued patents worldwide. Idun's corporate headquarters and research and development facility is located in San Diego, California. For more information please visit the company's web site at http://www.idun.com/.
Some of the statements in this press release are forward-looking statements and do not guarantee future performance and involve risks and uncertainties. Actual results may differ substantially from the results that the forward-looking statements suggest for various reasons. These forward- looking statements are made only as of the date of this press release.
CONTACT: Steven J. Mento, Ph.D., President and CEO of IdunPharmaceuticals, Inc., +1-858-623-1330; or Christopher Erdman of MacDougallBioCommunications, +1-508-647-0209, firstname.lastname@example.org, for IdunPharmaceuticals